Deals Of The Week: Celgene/Acetylon, Cytomedix/Aldagen, Vernalis/Tris Pharma
CEOs from Sanofi and GlaxoSmithKline hold forth on how previous years’ preparations have led up to this moment, a post-patent-cliff future for big pharma.
You may also be interested in...
Epigenetic modifiers are targeting a widening range of indications as growing knowledge of the underlying biology enables improved agents and therapeutic strategies. Nonetheless, issues of selectivity, toxicity, and finding adequate biomarkers still prevent the field from reaching its full potential.
Funded in part by the Israeli government, BioLineRx believes it is about to score big with a cardiology drug being developed under FDA’s regulatory pathway for devices, as well as a schizophrenia candidate that could improve patients’ cognition.
Sanofi will lose exclusivity for Plavix, Avapro and Eloxatin in 2012, driving what it expects will be a 12% to 15% EPS decline, but management is counting on a new wave of drugs – and the addition of Genzyme – to return to growth.